A new study from University of Oklahoma Department of Ophthalmology has found that daily use of medication called pirenzepine gel can slow down myopia progression in children, say researchers.
Myopia or nearsightedness is a condition in which focus on near objects is good, but distant objects appear blurry. Caused by a problem with the length of the eyeball or the curvature of the cornea, myopia gets worse over time in many children.
Myopia
Myopia is the inability of a person to see the distant objects clearly. Myopia is also known as near or short sightedness.
Advertisement
In the study led by Dr. R. Michael Stiatkowski of Dean McGee Eye Institute/University of Oklahoma Department of Ophthalmology, children with myopia were randomly assigned to treatment with pirenzepine gel or an inactive placebo gel. All children initially had "moderate" myopia, with an average refractive error of about -2.00 diopters.
Over a year of treatment, the team found that the average increase in myopia was significantly less for children using pirenzepine.
The new study presents the final results in 84 patients who continued treatment for a total of two years: 53 with pirenzepine and 31 with placebo.
![Short Sightedness - Animation]( "Short Sightedness - Animation")
Short Sightedness (Myopia) is a common vision problem, in which individuals cannot focus on distant objects and the images look blurred. This problem can be corrected with eyeglasses, contact lenses or surgery.
Although myopia worsened in both groups of children, the rate of progression was slower with pirenzepine.
At the end of two years, myopia increased by an average of 0.58 diopters in children using pirenzepine compared to 0.99 diopters with placebo.
New glasses are generally prescribed when myopia worsens by at least 0.75 diopters. During the study, 37 percent of children using pirenzepine met 0.75 diopters cut-off compared with 68 percent of the placebo group.
Treatments to slow worsening myopia could also have important quality-of-life benefits.
Previous studies have suggested that a drug called atropine can delay progression of myopia. The new results show that pirenzepine-a related drug with fewer side effects-is also safe and effective for this purpose.
The study appears in the August issue of the Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus).
Source: ANI
SRM
The new study presents the final results in 84 patients who continued treatment for a total of two years: 53 with pirenzepine and 31 with placebo.
Short Sightedness - Animation
Short Sightedness (Myopia) is a common vision problem, in which individuals cannot focus on distant objects and the images look blurred. This problem can be corrected with eyeglasses, contact lenses or surgery.
Advertisement
Although myopia worsened in both groups of children, the rate of progression was slower with pirenzepine.
At the end of two years, myopia increased by an average of 0.58 diopters in children using pirenzepine compared to 0.99 diopters with placebo.
New glasses are generally prescribed when myopia worsens by at least 0.75 diopters. During the study, 37 percent of children using pirenzepine met 0.75 diopters cut-off compared with 68 percent of the placebo group.
Treatments to slow worsening myopia could also have important quality-of-life benefits.
Previous studies have suggested that a drug called atropine can delay progression of myopia. The new results show that pirenzepine-a related drug with fewer side effects-is also safe and effective for this purpose.
The study appears in the August issue of the Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus).
Source: ANI
SRM
Laser Eye Surgery - Animation
Interactive section of Medindia gives general information about Laser Eye Surgery
Advertisement
 Vision Center - Online Vision GuideA list of eye tests to find out how healthy your eyes are. Contains a brief about visual accuracy test, distance acuity test and macular function test. Check for visual impairment and degeneration in any part of your eyes. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.